Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Incorporated in 1982, Immunomedics is a biopharmaceutical company focused on the development, manufacture and marketing of monoclonal antibody (MAb)-based products for the detection and treatment of cancer and other serious diseases. The company has developed a number of advanced proprietary technologies that allow it to create humanised Abs that can be used either alone in unlabelled form, or conjugated with radioactive isotopes, chemotherapeutics or toxins to create highly targeted agents. Using these technologies, Immunomedics has built a broad pipeline of therapeutic product candidates that utilise several different mechanisms of action. In addition to CEA-Scan, Immunomedics also markets another diagnostic imaging agent, LeukoScan, for the detection and diagnosis of osteomyelitis in long bones and in diabetic foot ulcer patients in the EU and Australia.